Marshall Wace
VOR icon

Marshall Wace’s Vor Biopharma VOR Stock Holding History

Marshall Wace’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Sell
95,643
-1,057,633
-92% -$16M ﹤0.01% 1927
2026
Q1 		$20.6M Buy
+1,153,276
New +$16.3M 0.02% 695
2025
Q2 		– Sell
-933
Closed -$13.4K – 3219
2025
Q1 		$13.4K Sell
933
-927
-50% -$22.3K ﹤0.01% 2569
2024
Q4 		$41.3K Sell
1,860
-3,972
-68% -$65.8K ﹤0.01% 2494
2024
Q3 		$81.6K Buy
5,832
+1,776
+44% +$32.4K ﹤0.01% 2394
2024
Q2 		$81.1K Buy
4,056
+240
+6% +$7.76K ﹤0.01% 2407
2024
Q1 		$181K Buy
+3,816
New +$168K ﹤0.01% 2252
2023
Q2 		– Sell
-2,504
Closed -$269K – 3000
2023
Q1 		$269K Buy
2,504
+980
+64% +$109K ﹤0.01% 2329
2022
Q4 		$203K Buy
+1,524
New +$151K ﹤0.01% 2700

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Marshall Wace's VOR Position: Q2 2026 in Review

Marshall Wace reduced its Vor Biopharma (VOR) stake by 92% in Q2 2026, selling an estimated $16M and leaving 95,643 shares worth $1.76M. The position accounts for ﹤0.01% of the portfolio, ranked #1927.

Marshall Wace first reported a position in VOR in Q4 2022 and has held it in 9 quarters since. The position peaked at $20.6M in Q1 2026. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Marshall Wace held 95,643 shares of Vor Biopharma worth $1.76M as of Q2 2026.
  • Marshall Wace sold 1,057,633 Vor Biopharma shares in Q2 2026, an estimated $16M.
  • Vor Biopharma made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1927 holding.
  • Marshall Wace first reported a position in Vor Biopharma in Q4 2022 and has held it in 9 quarters since.
  • Marshall Wace's Vor Biopharma position peaked at $20.6M in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.